The 54 references in paper S. Avdeev N., С. Авдеев Н. (2014) “Новые возможности противовоспалительной терапии хронической обструктивной болезни легких // Novel effects of antiinflammatory therapy of chronic obstructive pulmonary disease” / spz:neicon:pulmonology:y:2013:i:4:p:95-101

1
Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI / WHO workshop report. Last updated 2013. www.goldcopd.org
(check this in PDF content)
2
Celli B.R., MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS / ERS position paper. Eur. Respir. J. 2004; 23: 932–946.
(check this in PDF content)
3
Buist A.S., McBurnie M.A., Vollmer W.M. et al. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet 2007; 370: 741–750.
(check this in PDF content)
4
Barnes P.J., Shapiro S.D., Pauwels R.A. Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur. Respir. J. 2003; 22: 672–688.
(check this in PDF content)
5
Hogg J.C. Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. Lancet 2004; 364: 709–721.
(check this in PDF content)
6
Barnes P.J. Chronic obstructive pulmonary disease. N. Engl. J. Med. 2000; 343: 269–280.
(check this in PDF content)
7
Barnes P.J.Molecular genetics of chronic obstructive pulmonary disease. Thorax 1999; 54: 245–252.
(check this in PDF content)
8
Meshi B., Vitalis T.Z., Ionescu D. et al.Emphysematous lung destruction by cigarette smoke. The effects of latent adenoviral infection on the lung inflammatory response. Am. J. Respir. Cell. Mol. Biol. 2002; 26: 52–57.
(check this in PDF content)
9
Ito K., Lim S., Caramori G. et al. Cigarette smoking reduces histone deacetylase 2 expression, enhances cytokine expression and inhibits glucocorticoid actions in alveolar macrophages. FASEB J. 2001; 15: 1100–1102.
(check this in PDF content)
10
Martin C., Frija J., Burgel P.3R.Dysfunctional lung anatomy and small airways degeneration in COPD. Int. J. COPD 2013; 8: 7–13.
(check this in PDF content)
11
Hogg J.C.Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. Lancet 2004; 364: 709–721.
(check this in PDF content)
12
Rutgers S.R., Postma D.S., ten Hacken N.H. et al. Ongoing airway inflammation in patients with COPD who do not currently smoke. Thorax 2000; 55: 12–18.
(check this in PDF content)
13
Jen R., Rennard S.I., Sin D.D. Effects of inhaled corticosteroids on airway inflammation in chronic obstructive pulmonary disease: a systematic review and meta-analysis. Int. J. COPD 2012; 7: 587–595.
(check this in PDF content)
14
Antoniu S.A.New therapeutic options in the management of COPD – focus on roflumilast. Int. J. Chron. Obstruct. Pulm. Dis. 2011; 6: 147–155.
(check this in PDF content)
15
Hatzelmann A., Morcillo E.J., Lungarella G. et al. The preclinical pharmacology of roflumilast – a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease. Pulm. Pharmacol. Ther. 2010; 23: 235–256.
(check this in PDF content)
16
Grootendorst D.C., Gauw S.A., Verhoosel R.M. et al. The PDE4 inhibitor roflumilast reduces sputum neutrophil and eosinophil numbers in patients with COPD. Thorax 2007; 62: 1081–1087.
(check this in PDF content)
17
Rabe K.F., Bateman E.D., O'Donnell D. et al. Roflumilast – an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomized controlled trial. Lancet 2005; 366: 563–571.
(check this in PDF content)
18
Kardos P., Makros I., Vogelmeier C. Effect of roflumilast on quality of life in frequent and infrequent exacerbators. In: ERS Annual congress. 2013. P4150.
(check this in PDF content)
19
Calverley P.M., Sanchez3Toril F., McIvor A. et al.Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med.
(check this in PDF content)
20
7; 176: 154–161. 20.Calverley P.M., Rabe K.F., Goehring U.M. et al.Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 2009; 374: 685–694.
(check this in PDF content)
21
Wedzicha J.A., Rabe K.F., Martinez F.J. et al.Roflumilast for the frequent exacerbator phenotype. Chest 2013; 143: 1302–1311.
(check this in PDF content)
22
Fabbri L.M., Calverley P.M., Izquierdo3Alonso J.L. et al. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet 2009; 374: 695–703.
(check this in PDF content)
23
Rennard S.I., Calverley P.M.A., Goehring U.M. et al. Reduction of exacerbations by the PDE4 inhibitor roflumilast – the importance of defining different subsets of patients with COPD. Respir. Res. 2011, 12: 18.
(check this in PDF content)
24
Calverley P., Fabbri L., Martinez F. et al.Efficacy of roflumilast with concomitant cardiovascular medication in patients with COPD. In: ERS Annual congress. 2013. P3034.
(check this in PDF content)
25
Oba Y., Lone N.A.Efficacy and safety of roflumilast in patients with chronic obstructive pulmonary disease. A systematic review and meta-analysis. Ther. Adv. Respir. Dis. 2013; 7: 13–24.
(check this in PDF content)
26
FDA. Centre for Drug Evaluation and Research. Application number 022522Orig1s000. Medical Review(s). Available at http://wwwaccessdatafdagov/drugsatfda_docs/ nda/2011/022522Orig1s000MedRpdf.
(check this in PDF content)
27
Tenor H., Beume R., Lahu G. et al. Pharmacology, clinical efficacy and tolerability of phosphodiesterase-4 inhibitors: impact of human pharmacokinetics. In: Francis S.H. et al., eds. In: Phosphodiesterases as drug targets. Handbook of experimental pharmacology. Berlin Heidelberg: SpringerVerlag; 2011.
(check this in PDF content)
28
Карпечкина Ю.Л.Распространенность, особенности клинического течения и лечения ХОБЛ на фоне метаболического синдрома: клинико-патогенетическое исследование: Автореф. дис. ... канд. мед. наук. М.; 2010.
(check this in PDF content)
29
Akpinar E.E., Akpinar S., Ertek S. et al. Systemic inflammation and metabolic syndrome in stable COPD patients. Tuberk. Toraks. 2012; 60: 230–237.
(check this in PDF content)
30
Visser M., Bouter L.M., McQuillan G.M. et al. Elevated C-reactive protein levels in overweight and obese adults. J.A.M.A. 1999; 282: 2131–2135.
(check this in PDF content)
31
Rexrode K.M., Pradhan A., Manson J.E. et al. Relationship of total and abdominal adiposity with CRP and IL-6 in women. Ann. Epidemiol. 2003; 13: 674–682.
(check this in PDF content)
32
Martinez F., Rabe K., Wouters E. et al. Time course and reversibility of weight decrease with roflumilast, a phosphoАвдеев С.Н. Новые возможности противовоспалительной терапии хронической обструктивной болезни легких diesterase inhibitor. Am. J. Respir. Crit. Care Med. 2010; 181: A4441.
(check this in PDF content)
33
Wouters E.F., Bredenbroker D., Teichmann P. et al. Effect of the phosphodiesterase 4 inhibitor roflumilast on glucose metabolism in patients with treatment-naive, newly diagnosed type 2 diabetes mellitus. J. Clin. Endocrinol. 2012; 97: E1720–E1725.
(check this in PDF content)
34
Wouters E.F.M., Teichmann P., Brose M. et al. Effects of roflumilast, a phosphodiesterase 4 inhibitor, on glucose homeostasis in patients with treatment-naive diabetes (type 2). Am. J. Respir. Crit. Care Med. 2010; 181: A4471.
(check this in PDF content)
35
Hansell A.L., Walk J.A., Soriano J.B. What do chronic obstructive pulmonary disease patients die from? A multiple cause coding analysis. Eur. Respir. J. 2003; 22: 809–814.
(check this in PDF content)
36
Janssens J.P., Herrmann F., MacGee W., Michel J.P. Cause of death in older patients with anatomo-pathological evidence of chronic bronchitis or emphysema: a case-control study based on autopsy findings. J. Am. Geriatr. Soc. 2001; 49: 571–576.
(check this in PDF content)
37
Rutten F.H., Moons K.G., Cramer M.J. et al. Recognising heart failure in elderly patients with stable chronic obstructive pulmonary disease in primary care: cross-sectional diagnostic study. Br. Med. J. 2005; 331: 1379.
(check this in PDF content)
38
Engstrom G., Wollmer P., Hedblad B. et al. Occurrence and prognostic significance of ventricular arrhythmia is related to pulmonary function: a study from "men born in 1914", Malmö, Sweden. Circulation 2001; 103: 3086–3091.
(check this in PDF content)
39
Huiart L., Ernst P., Suissa S.Cardiovascular morbidity and mortality in COPD. Chest 2005; 128: 26400–2646.
(check this in PDF content)
40
Rosengren A., Wilhelmsen L.Respiratory symptoms and long-term risk of death from cardiovascular disease, cancer and other causes in Swedish men. Int. J. Epidemiol. 1998; 27: 962–969.
(check this in PDF content)
41
Anthonisen N.R., Skeans M.A., Wise R.A. et al. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann. Intern. Med. 2005; 142: 233–239.
(check this in PDF content)
42
Wieshammer S., Dreyhaupt J., Basler B. A Link between impaired lung function and increased cardiac stress. Respiration 2010; 79: 355–362.
(check this in PDF content)
43
Sin D.D., Man S.F. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 2003; 107: 1514–1519.
(check this in PDF content)
44
Tashkin D.P., Celli B., Senn S. et al.UPLIFT Study Investigators. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N. Engl. J. Med. 2008; 359: 1543–1554.
(check this in PDF content)
45
Calverley P.M., Anderson J.A., Celli B. et al. TORCH Investigators. Cardiovascular events in patients with COPD: TORCH study results. Thorax 2010; 65: 719–725.
(check this in PDF content)
46
Calverley P.M., Anderson J.A., Celli B. et al. TORCH investigators. Salmeterol and fluticasone proprionate and survival in chronic obstructive pulmonary disease. N. Engl. J. Med. 2007; 356: 775–789.
(check this in PDF content)
47
White W.B., Cooke G.E., Kowey P.R. et al.Cardiovascular safety in patients receiving roflumilast for the treatment of chronic obstructive pulmonary disease. Chest 2013; 144: 758–765.
(check this in PDF content)
48
Takabatake N., Nakamura H., Abe S. et al. The relationship between chronic hypoxemia and activation of the tumor necrosis factor-alpha system in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2000; 161: 1179–1184.
(check this in PDF content)
49
Eid A.A., Ionescu A.A., Nixon L.S. et al. Inflammatory response and body composition in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2001; 164: 1414–1418.
(check this in PDF content)
50
Schols A.M., Buurman W.A., Staal van den Brekl A.J. et al. Evidence for a relation between metabolic derangements and increased levels of inflammatory mediators in a subgroup of patients with chronic obstructive pulmonary disease. Thorax 1996; 51: 819–824.
(check this in PDF content)
51
Hatzelmann A., Schudt C.Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro. J. Pharmacol. Exp. Ther. 2001; 297: 267–279.
(check this in PDF content)
52
Bundschuh D.S., Eltze M., Barsig J. et al. In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor. J. Pharmacol. Exp. Ther. 2001; 297: 280–290.
(check this in PDF content)
53
Barnes N.C., Qiu Y.3S., Pavord I.D. et al. Antiinflammatory effects of salmeterol / fluticasone propionate in chronic obstructive lung disease. Am. J. Respir. Crit. Care Med. 2006; 173: 736–743.
(check this in PDF content)
54
Kardos P., Makros I., Vogelmeier C.Effect of roflumilast on quality of life in frequent and infrequent exacerbators. ERS Annual Congress 2013: P4150. Информация об авторе Авдеев Сергей Николаевич – д. м. н., профессор, руководитель клини-
(check this in PDF content)